insights_auto
Pourquoi CTSO a-t-elle baissé de 12,31%?
Approfondirchevron_right
CTSO:NASDAQ
Cytosorbents
5,27 $US
arrow_downward
-12,31%(-0,74) 1J
5,12 $US
arrow_downward
-2,93% (-0,15)bedtimeAprès clôture
Fermé : 23 oct., 16:00:01 UTC−4 · USD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour CTSO...
Ouverture
5,90 $US
Élevé
5,96 $US
Faible
5,22 $US
Cap. boursière
16,61 M
Vol. moyen
46,62 k
Volume
43,06 k
+ haut sur 1 an
17,28 $US
+ bas sur 1 an
2,84 $US
BPA
-5,80 $US
Bêta
1,37
Actions en circulation
3,15 M
Nombre d'employés
129
Ouverture
5,90 $US
Élevé
5,96 $US
Faible
5,22 $US
Cap. boursière
16,61 M
Vol. moyen
46,62 k
Volume
43,06 k
+ haut sur 1 an
17,28 $US
+ bas sur 1 an
2,84 $US
BPA
-5,80 $US
Bêta
1,37
Actions en circulation
3,15 M
Nombre d'employés
129
Articles
Sources : Web et partenaires du secteur de l'information
Benzinga
·
il y a 1 jour
12 Health Care Stocks Moving In Friday's After-Market Session
Profil
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
À propos de Cytosorbents